ABUS Arbutus Biopharma Corp
Price (delayed)
$4.09
Market cap
$772.12M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.45
Enterprise value
$710.93M
Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple
Highlights
The debt has declined by 22% year-on-year and by 5% since the previous quarter
Arbutus Biopharma's equity has decreased by 9% YoY but it has increased by 7% QoQ
The company's EPS fell by 2.3% QoQ but it rose by 2.2% YoY
Arbutus Biopharma's gross profit has shrunk by 57% YoY and by 23% QoQ
Arbutus Biopharma's revenue has shrunk by 57% YoY and by 23% QoQ
Key stats
What are the main financial stats of ABUS
Market
Valuations
Earnings
Shares outstanding
188.78M
Market cap
$772.12M
Enterprise value
$710.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.3
Price to sales (P/S)
76.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
70.66
Revenue
$10.06M
EBIT
-$76.92M
EBITDA
-$75.48M
Free cash flow
-$72.98M
Per share
Balance sheet
Liquidity
EPS
-$0.45
Free cash flow per share
-$0.39
Book value per share
$0.65
Revenue per share
$0.05
TBVPS
$0.85
Total assets
$160.04M
Total liabilities
$37.59M
Debt
$1.6M
Equity
$122.45M
Working capital
$125.63M
Debt to equity
0.01
Current ratio
6.56
Quick ratio
6.36
Net debt/EBITDA
0.81
Margins
Efficiency
Dividend
EBITDA margin
-750.2%
Gross margin
100%
Net margin
-766.2%
Operating margin
-819.3%
Return on assets
-50.3%
Return on equity
-66.7%
Return on invested capital
-80.3%
Return on capital employed
-56%
Return on sales
-764.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABUS stock price
How has the Arbutus Biopharma stock price performed over time
Intraday
0.25%
1 week
-10.31%
1 month
10.24%
1 year
105.53%
YTD
63.6%
QTD
32.36%
Financial performance
How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$10.06M
Gross profit
$10.06M
Operating income
-$82.43M
Net income
-$77.09M
Gross margin
100%
Net margin
-766.2%
ABUS's operating margin has dropped by 158% year-on-year and by 33% since the previous quarter
The net margin has dropped by 147% year-on-year and by 34% since the previous quarter
Arbutus Biopharma's gross profit has shrunk by 57% YoY and by 23% QoQ
Arbutus Biopharma's revenue has shrunk by 57% YoY and by 23% QoQ
Growth
What is Arbutus Biopharma's growth rate over time
Valuation
What is Arbutus Biopharma stock price valuation
P/E
N/A
P/B
6.3
P/S
76.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
70.66
The company's EPS fell by 2.3% QoQ but it rose by 2.2% YoY
ABUS's price to book (P/B) is 125% higher than its 5-year quarterly average of 2.8 and 61% higher than its last 4 quarters average of 3.9
Arbutus Biopharma's equity has decreased by 9% YoY but it has increased by 7% QoQ
The price to sales (P/S) is 197% higher than the 5-year quarterly average of 25.7 and 133% higher than the last 4 quarters average of 32.7
Arbutus Biopharma's revenue has shrunk by 57% YoY and by 23% QoQ
Efficiency
How efficient is Arbutus Biopharma business performance
The company's return on sales has shrunk by 150% YoY and by 34% QoQ
The ROIC has dropped by 52% year-on-year and by 18% since the previous quarter
Arbutus Biopharma's return on assets has decreased by 32% YoY and by 7% QoQ
The ROE is down by 28% year-on-year and by 6% since the previous quarter
Dividends
What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABUS.
Financial health
How did Arbutus Biopharma financials performed over time
ABUS's total liabilities is down by 11% year-on-year but it is up by 5% since the previous quarter
The company's total assets fell by 9% YoY but it rose by 6% QoQ
The debt is 99% smaller than the equity
ABUS's debt to equity has dropped by 50% year-on-year
The debt has declined by 22% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.